SCHEMBL1364033

SCHEMBL1364033

CN(C)c1c(NC(=O)c2c(F)cccc2F)cccc1-c1nc2sccn2c1-c1ccnc(Nc2cccc(N3CCOCC3)c2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 10/20 1.00
KDR P35968 10/20 1.00
MAP4K4 O95819 7/20 1.00
ABL1 P00519 2/20 1.00
RET P07949 8/20 0.77
DYRK1A Q13627 1/20 0.77
IGF1R P08069 16/20 0.76
EGFR P00533 11/20 0.76
ERBB2 P04626 11/20 0.76
MAP4K5 Q9Y4K4 9/20 0.74
FYN P06241 6/20 0.74
MINK1 Q8N4C8 4/20 0.74
BTK Q06187 2/20 0.74
STK3 Q13188 8/20 0.68
AURKB Q96GD4 7/20 0.68
PTK2 Q05397 5/20 0.68
MAP4K2 Q12851 5/20 0.68
CSF1R P07333 6/20 0.63
TAOK1 Q7L7X3 6/20 0.63
FGFR1 P11362 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364445 0.91 LCK (0.88) LCKKDRMAP4K4ABL1RET
SCHEMBL1363249 0.87 LCK (1.00) LCKKDRMAP4K4ABL1RET
SCHEMBL1363836 0.86 IGF1R (1.00) LCKKDRMAP4K4ABL1RET
SCHEMBL1363931 0.85 LCK (1.00) LCKKDRMAP4K4ABL1RET
SCHEMBL1362565 0.82 EGFR (1.00) LCKKDRMAP4K4ABL1RET
SCHEMBL1362484 0.81 IGF1R (1.00) LCKKDRMAP4K4ABL1RET
SCHEMBL1364762 0.81 IGF1R (0.89) LCKKDRMAP4K4ABL1RET
SCHEMBL1362348 0.81 IGF1R (0.82) LCKKDRMAP4K4ABL1RET
SCHEMBL1364681 0.79 EGFR (0.83) LCKKDRMAP4K4ABL1RET
SCHEMBL1362422 0.79 EGFR (0.86) LCKKDRMAP4K4ABL1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 LCK 111/4885KDR 1617/4885MAP4K4 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.